MedTrace Logo

Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

NCT02821494 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-02-21

No results posted yet for this study

Summary

A phase I study to establish the highest safe dose that induces HPV16 E6-specific T-cell responses, using the highly promising novel therapeutic vaccine concept named: Hespecta (HPV E Six Peptide Conjugated To Amplivant®) to induce HPV16 E6-specific T-cell responses.

Conditions

  • Tumors or Premalignant Lesions

Interventions

BIOLOGICAL

Hespecta

A dose escalation of Amplivant® conjugated peptide

Sponsors & Collaborators

  • ISA Pharmaceuticals

    collaborator INDUSTRY

  • Dutch Cancer Society

    collaborator OTHER

  • Top Institute Pharma

    collaborator OTHER

  • Leiden University

    lead OTHER

Principal Investigators

  • H. Gelderblom, Prof.dr. · Leiden University Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02821494 on ClinicalTrials.gov